Efficacy and safety of favipiravir in patients with COVID-19: a review of systematic reviews and metaanalysis
Urmia Medical Journal
; 32(10):782-792, 2022.
Article
in English
| GIM | ID: covidwho-2012533
ABSTRACT
Background & Aims:
Favipiravir is an antiviral drug that is widely used in patients with Covid-19. The aim of this study was to review the systematic review and meta-analysis studies of Favipiravir in patients with Covid-19. Materials &Methods:
An electronic search was conducted in PubMed, Scopus, Cochrane Library, and Web of Science databases until December 2021. In addition, other databases were searched. A manual search of studies and other sources was also conducted to find evidence. The Overview Quality Assessment Questionnaire tool was used to evaluate the quality of articles.
259793-96-9; human diseases; coronavirus disease 2019; viral diseases; pandemics; public health; efficacy; safety; drug therapy; favipiravir; patients; literature reviews; systematic reviews; meta-analysis; antiviral agents; mortality; risk reduction; treatment outcomes; epidemiology; case-control studies; reverse transcriptase PCR; artificial respiration; adverse effects; man; Severe acute respiratory syndrome coronavirus 2; Homo; Hominidae; primates; mammals; vertebrates; Chordata; animals; eukaryotes; Severe acute respiratory syndrome-related coronavirus; Betacoronavirus; Coronavirinae; Coronaviridae; Nidovirales; positive-sense ssRNA Viruses; ssRNA Viruses; RNA Viruses; viruses; SARS-CoV-2; viral infections; chemotherapy; antivirals; death rate; reverse transcriptase polymerase chain reaction; Rt-pcr; adverse reactions
Search on Google
Collection:
Databases of international organizations
Database:
GIM
Type of study:
Reviews
/
Systematic review/Meta Analysis
Language:
English
Journal:
Urmia Medical Journal
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS